Transforming Data Into Better Healthcare By Dr Jens Hoefkens The healthcare industry is drowning in data for which it lacks established data analysis processes. This situation exists despite the fact that appropriate and efficient data analysis processes are keys to better decision-making and enhanced healthcare therapies, which can potentially result… Read More
Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. The short supply… Read More
Fragment Library Design - The Evolution Of Fragment Based Lead Discovery By Dr Edward Zartler, Dr Chris Swain and Simon Pearce With the growing need to streamline the drug discovery process, screening against fragment libraries rather than drug-like molecules has become increasingly adopted as an integral part of many drug… Read More
Induced pluripotent stem cells in high-throughput cellular screening By Dr Carolyn E. Peluso With the failure rates of drug candidates continuing to present phenomenal costs to the pharmaceutical industry, this article discusses how newly emerging induced pluripotent stem cell (iPSC) technologies have the potential to be an effective tool in… Read More
Targeting Tau For Alzheimer’s Disease and Related Neurodegenerative Disorders By Dr Eliot J. Davidowitz and Dr James G. Moe There is no effective treatment for Alzheimer’s disease (AD) even though the prevalence of this neurodegenerative disorder and its associated costs are growing along with an ageing population. This article discusses… Read More
Meeting the challenge of healthcare-associated infections with new antimicrobials: with a focus on Clostridium difficile By Professor Peter Hawkey and Dr Katie Hardy Healthcare-associated infections (HCAI), previously known as hospital acquired infections (HAI), are defined as infections resulting from medical care or treatment in hospital. HCAI may be caused by… Read More
Epigenetics: Are We Hitting The Mark? By Dr Andrew J. Pope and Dr Amy M. Quinn During the last few years, advances in the understanding of epigenetic processes have led to an explosion in interest in this area as a potential source of new targets for the discovery of medicines. Read More
Enzyme-linked Immunosorbent Assays (ELISA): Recent Innovations Take Analyte Detection To New Levels By Dr John Comley Enzyme-linked immunosorbent assays (ELISA) have been around as one of the primary methods of analyte detection for more than four decades. Over the years many changes to the basic format have resulted in assay… Read More
The Challenges Of The Changing Drug Discovery Model By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management and communication of… Read More
Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry By Dr Yi Gu and William Shi As the third-largest market for the pharmaceutical industry, the China/Asia region is becoming increasingly important. The AstraZeneca Innovation Center China (ICC) in Shanghai is perfectly positioned to benefit from close proximity to key opinion… Read More
Editing the Human Genome: Role in Functional Genomics and Translational Medicine By Dr Chris Torrance and Eric Rhodes It is now readily accepted that we are in a post genomic era. With the steady flow of genomic information available to researchers worldwide, the focus turns to ways to analyse this… Read More
New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high content screening assays today; the motivation to… Read More
Ubiquitination, E3 Ligases and Drug Discovery - Novel technologies for a challenging pathway By Dr Neil Wilkie and Dr Steve Davies Does ubiquitin drug discovery provide the opportunity for a new class of therapeutic agents? This article argues that new technological advances are removing many of the barriers that have… Read More
Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their ability to… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in the genomics… Read More
By Dr Jeffrey Dage and Dr Kalpana Merchant While the jury is still out in terms of iPS cell technology and its ability to deliver a regenerative therapy or, indeed, contribute to the development of a clinical molecule, this paper argues that the progress by which this technology has been… Read More
